Download PDF

1. Company Snapshot

1.a. Company Description

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.


The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system.OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Show Full description

1.b. Last Insights on OCX

The recent 3 months performance of OncoCyte Corporation was negatively impacted by the company's failure to meet expectations in its Q1 2025 earnings release. Despite positive updates on clinical trial progress and the launch of its GraftAssure RUO assay in July 2024, the company's revenue growth was sluggish, with Q4 2024 revenue of $1.5 million in pharma services and full-year revenue of $1.9 million. The company's reliance on a single revenue stream and its limited product portfolio may have contributed to its slow growth. Additionally, the company's decision to participate in the 24th Annual Needham Virtual Healthcare Conference in April 2025 may have been overshadowed by its disappointing earnings release.

1.c. Company Highlights

2. Insight Molecular: GraftAssure Milestone Amid Cash Burn

Insight Molecular Diagnostics reported a negative EPS of –$0.30422, slightly below analysts’ –$0.24 estimate, reflecting a continued loss as the company pours capital into FDA‑approved product development. Revenue, while still modest, is positioned for a projected 200 % growth next year, underscoring a strategy focused on rapid scale rather than immediate profitability.

Publication Date: Apr -21

📋 Highlights
  • FDA Submission Milestone:: GraftAssureDx for kidney transplants submitted for FDA review after $26M funding, aiming to expand to heart transplants via 510(k) pathway with 90-day review.
  • Financial Allocation:: Maintenance spending at $5.5M/quarter, growth at $2M/quarter, with cash burn expected to drop to $6M in H2 2024 from $8M in H1.
  • Market Expansion:: Engaged 37 US transplant centers, targeting $1M annual revenue per center, with a $2B total addressable market for dd-cfDNA testing.
  • Reimbursement Support:: Medicare reimburses GraftAssure at $27.53, with Z code submission underway to streamline billing and MAC-based reimbursement processes.
  • Validation & Performance:: University hospital head-to-head data showed GraftAssure equivalent to a national lab, detecting rejection 10-11 months earlier than standard care.

FDA Submission Milestone

The company successfully filed GraftAssureDx for 510(k) review, a critical step that could unlock a 90‑day FDA clearance window. Staff emphasized that “the submission is a key lever for market entry and reimbursement” (Staff, 2026 Q4 Earnings Call). This move positions Insight to secure Medicare reimbursement at $27.53 per test.

Commercialization Strategy

Insight’s commercialization roadmap targets 37 U.S. transplant centers, each projected to generate roughly $1 million annually. The firm will launch research‑use‑only marketing in 2026, funnel samples to its Tennessee lab, and pursue UK/EU approval, thereby expanding the product’s geographic footprint and revenue base.

Market Opportunity & Pricing

With a total addressable market exceeding $2 billion, the company’s strategy hinges on becoming the de‑facto dd‑cfDNA standard. Medicare’s $27.53 reimbursement, coupled with the test’s 10‑11‑month lead time for rejection detection, could drive adoption and justify premium pricing.

R&D & Operational Spending

Q4 R&D expenses rose due to software development, clinical trial costs, and FDA submission materials. Maintenance spending sits at $5.5 million per quarter, while growth spend is $2 million quarterly. Non‑GAAP EPS and adjusted EBITDA tables were incorporated to provide clearer profitability metrics.

Revenue Pipeline & Partnerships

Insight is engaging 4–5 heart‑transplant centers for a 150‑patient study, capitalizing on the 25–30 % of U.S. testing that serves heart transplants. Head‑to‑head data from a major university hospital shows GraftAssure’s results match national reference labs, bolstering the company’s value proposition.

Cash Flow & Burn

The firm forecasts $8 million in cash burn for the first half of the year, dropping to $6 million in the second half, a reflection of timing differences between spending and revenue realization. OpEx is expected to rise, but R&D spend will decline as the product nears market launch.

Valuation & Outlook

Current valuation metrics are heavily discounted: P/E –2.42, P/B –3.86, P/S 26.41, EV/EBITDA –3.49, and Net Debt/EBITDA 0.28. These figures underscore a market that penalizes the company’s negative earnings and high burn while still betting on future upside from GraftAssure’s market penetration and reimbursement strategy.

3. NewsRoom

Card image cap

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Jun -17

Source: globenewswire.com

Card image cap

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May -19

Source: globenewswire.com

Card image cap

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May -13

Source: seekingalpha.com

Card image cap

Oncocyte Reports Q1 2025 Results and Business Progress

May -12

Source: globenewswire.com

Card image cap

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May -07

Source: globenewswire.com

Card image cap

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May -07

Source: prismmediawire.com

Card image cap

Best Momentum Stocks to Buy for May 6th

May -06

Source: zacks.com

Card image cap

New Strong Buy Stocks for May 6th

May -06

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Diagnostic Tests

Expected Growth: 11.3%

OncoCyte Corporation's 11.3% growth in Diagnostic Tests is driven by increasing demand for early cancer detection, adoption of liquid biopsy technology, and expansion into new markets. Additionally, strategic partnerships, investments in R&D, and growing awareness of personalized medicine contribute to the segment's growth.

7. Detailed Products

DetermaRx

A non-invasive, liquid biopsy test for early detection of lung cancer

DetermaIO

A non-invasive, liquid biopsy test for immunotherapy response monitoring

DetermaTx

A non-invasive, liquid biopsy test for early detection of breast cancer

8. OncoCyte Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

OncoCyte Corporation's liquid biopsy tests are highly specialized and require significant expertise, making it difficult for substitutes to emerge.

Bargaining Power Of Customers

While customers have some bargaining power due to the availability of alternative diagnostic tests, OncoCyte's proprietary technology and strong relationships with healthcare providers mitigate this power.

Bargaining Power Of Suppliers

OncoCyte Corporation has a diversified supplier base, and the cost of switching suppliers is relatively low, reducing the bargaining power of suppliers.

Threat Of New Entrants

The liquid biopsy market is rapidly growing, and new entrants are attracted to the market, increasing the threat of new entrants for OncoCyte Corporation.

Intensity Of Rivalry

The liquid biopsy market is highly competitive, with multiple established players and new entrants, leading to a high intensity of rivalry for OncoCyte Corporation.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 10.08%
Debt Cost 3.95%
Equity Weight 89.92%
Equity Cost 7.95%
WACC 7.54%
Leverage 11.21%

11. Quality Control: OncoCyte Corporation passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
OncoCyte

A-Score: 4.7/10

Value: 7.1

Growth: 5.9

Quality: 3.1

Yield: 0.0

Momentum: 8.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
2seventy bio

A-Score: 4.3/10

Value: 7.7

Growth: 4.4

Quality: 4.6

Yield: 0.0

Momentum: 8.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Seer

A-Score: 4.1/10

Value: 8.2

Growth: 4.2

Quality: 4.5

Yield: 0.0

Momentum: 3.5

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Biomea Fusion

A-Score: 3.3/10

Value: 6.9

Growth: 3.4

Quality: 4.1

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Vir Biotechnology

A-Score: 3.3/10

Value: 7.8

Growth: 3.6

Quality: 5.0

Yield: 0.0

Momentum: 2.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Pliant Therapeutics

A-Score: 2.6/10

Value: 8.0

Growth: 3.1

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.2$

Current Price

3.2$

Potential

-0.00%

Expected Cash-Flows